Baricitinib 2 MG [Olumiant] ( DrugBank: Baricitinib )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 1 |
162. 類天疱瘡（後天性表皮水疱症を含む。）
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05263505 (ClinicalTrials.gov) | February 21, 2022 | 16/2/2022 | Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid | Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid | Mucous Membrane Pemphigoid;Cicatrizing Conjunctivitis | Drug: Baricitinib 2 MG [Olumiant];Drug: Methotrexate;Drug: Azathioprine;Drug: Mycophenolate | Washington University School of Medicine | Eli Lilly and Company | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |